Market Overview

UPDATE: Credit Suisse Raises PT to $44 on Forest Laboratories on Positive Linzess Survey

Related FRX
Icahn's (Potential) Move Into Biotech
Carl Icahn's Track Record In Big Pharma

Credit Suisse maintained Forest Laboratories (NYSE: FRX) with an Outperform rating and raised the price target from $42.00 to $44.00.

Credit Suisse analyst Catherine Arnold noted, "Credit Suisse proprietary market research survey with approx. 100 physicians implies greater demand via both category expansion and competitive market share. Respondents include 55% gastroenterologists and 45% PCPs of which ~70% early Linzess users and all with brand awareness."

Forest Laboratories closed at $37.93 on Thursday.

Latest Ratings for FRX

May 2014UBSMaintainsNeutral
Apr 2014Cantor FitzgeraldMaintainsHold
Apr 2014SunTrust Robinson HumphreyDowngradesBuyNeutral

View More Analyst Ratings for FRX
View the Latest Analyst Ratings

Posted-In: Credit SuisseAnalyst Color Price Target Analyst Ratings


Related Articles (FRX)

View Comments and Join the Discussion!

Partner Center